StockNews.com Upgrades GSK (NYSE:GSK) to Strong-Buy

GSK (NYSE:GSK - Get Free Report) was upgraded by stock analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Monday.

A number of other analysts have also recently weighed in on GSK. Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Guggenheim cut GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Finally, Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and decreased their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $43.25.

GSK Trading Down 2.0 %

NYSE GSK opened at $33.08 on Monday. The company's 50-day simple moving average is $34.38 and its two-hundred day simple moving average is $38.17. GSK has a one year low of $32.83 and a one year high of $45.92. The company has a market capitalization of $68.56 billion, a price-to-earnings ratio of 21.48, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. FMR LLC lifted its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Primecap Management Co. CA lifted its position in GSK by 13.9% during the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company's stock worth $558,689,000 after buying an additional 1,773,020 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in GSK during the second quarter worth $52,487,000. Fisher Asset Management LLC boosted its stake in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after buying an additional 870,449 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its holdings in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock valued at $144,803,000 after buying an additional 833,080 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.